Mylan Comments on Teva's Agreement to Acquire Allergan's Generic Drug Unit

Canaccord Genuity Raises Price Target on Teva Pharma (TEVA) Following Announced Acquisition of Allergan Generics

Canaccord Genuity maintained a Hold rating on Teva Pharma (NYSE: TEVA), and raised the price target to $79.00 (from $63.00), following the announced acquisition of Allergan Generics for $40.5B - $33.75B in cash and $6.75B in stock. Analyst Corey Davis said that this is not a good signal about the overall future of the... More

Leerink Partners Raises Price Target to $84 on Teva Pharma (TEVA) Following Call with CFO

Leerink Partners reiterated an Outperform rating on Teva Pharma (NYSE: TEVA), and raised the price target to $84.00 (from $74.00), following a call with CFO Eyal Desheh. The TEVA-AGN deal is estimated to close in 1Q'16 and management still anticipates holding its annual guidance... More

Mylan's (MYL) Price Target Reduced to $65 at Deutsche Bank

Deutsche Bank maintained a Buy rating on Mylan (NASDAQ: MYL) but cut its price target to $65.00 (from $82.00). The change reflects standalone valuation after Teva Pharma (NYSE: TEVA) earlier withdrew its agreement to acquired the company.

"Following TEVAs announced plan to acquire Allergan... More

Teva Pharma (TEVA) PT Raised to $74 at Maxim Group on Deal for Allergan's Generic Drug Business

Maxim Group analyst Jason Kolbert reiterated a Buy rating and raised his price target on Teva Pharma (NYSE: TEVA) to $74.00 (from $64.00) after the company agreed to acquire Allergan's legacy Actavis global generics business. The company is dropping its bid for... More

Cowen Downgrades Mylan (MYL) to Market Perform

Cowen downgraded Mylan (NASDAQ: MYL) from Outperform to Market Perform.

For an analyst ratings summary and ratings history on Mylan click here. For more ratings news on Mylan click here.

Shares of Mylan closed at $65.94 yesterday.

Mylan (MYL) Comments on Teva/Allergan Deal; Strategic Focus Remains Unchanged

Mylan (Nasdaq: MYL) issued the following statement regarding Teva's (NYSE: TEVA) announcement of its entry into an agreement to acquire Allergan's (NYSE: AGN) Generic Drug Unit and its withdrawal of its unsolicited expression of interest to acquire Mylan.

Mylan... More